<DOC>
	<DOC>NCT00803920</DOC>
	<brief_summary>The purpose of this substudy is to obtain CGM data from individuals taking exenatide. The CGM measurements gathered before starting and during treatment with exenatide IR and/or exenatide LAR will help determine the characteristics of glucose control during treatment.</brief_summary>
	<brief_title>Continuous Glucose Monitoring (CGM) in Subjects With Type 2 Diabetes Taking Twice-Daily Exenatide or Once-Weekly Exenatide</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Exenatide</mesh_term>
	<criteria>participant in Amylin Protocol 2993LAR105 at least 16 years of age type 2 diabetes being treated with stable regiment of metformin, SU, TZD, combination of metformin/SU, combination metformin/TZD, combination SU/TZD A1c 7.1 11 fasting glucose less than 280 at screening BMI 25 45 stable body weight 6 months prior to screening not pregnant and willing to practice birth control physical exam &amp; ECG not clinically significant lab values judged not to be clinically significant able to understand &amp; sign consent form clinically significant medical condition as judged by investigator drug or alcohol abuse previous use of exenatide or any GLP1 analog has used any investigational drug in the past 30 days prior to screening is currently using: alphaglucosidase inhibitor, insulin, drugs that affect GI motility, use of systemic corticosteroids, use of medications with addictive potential, prescription or OTC weightloss medications has donated blood within 60 days of screening, or is planning to donate during the study has had major surgery or blood transfusion within 2 months of screening has had a surgical procedure that may impact gastric emptying has any allergies or hypersensitivity to any component of study treatment is an immediate family member of personnel affiliated with the study at the investigative site is employed by Amylin, Lilly or Alkermes</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2013</verification_date>
	<keyword>exenatide twice daily or once weekly</keyword>
	<keyword>continuous glucose monitoring</keyword>
</DOC>